NGM Biopharmaceuticals, Inc. (NGM) Tops Q4 EPS by 7c

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $6.77 million.

For earnings history and earnings-related data on NGM Biopharmaceuticals, Inc. (NGM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49